

# Wolfgang H Jost

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6498612/publications.pdf>

Version: 2024-02-01

181  
papers

6,113  
citations

101384

36  
h-index

91712

69  
g-index

243  
all docs

243  
docs citations

243  
times ranked

4565  
citing authors

#	ARTICLE	IF	CITATIONS
1	Implications of dopaminergic medication withdrawal in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2022, 129, 1169-1178.	1.4	9
2	A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2022, 129, 723-736.	1.4	23
3	Diffusion microstructure imaging in progressive supranuclear palsy: reduced axonal volumes in the superior cerebellar peduncles, dentato-rubro-thalamic tracts, ventromedial thalamus, and frontomesial white matter. <i>Cerebral Cortex</i> , 2022, 32, 5628-5636.	1.6	6
4	Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus. <i>Npj Parkinson's Disease</i> , 2022, 8, 17.	2.5	7
5	Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management. <i>Npj Parkinson's Disease</i> , 2022, 8, 31.	2.5	53
6	Gastrointestinal Disturbances in Parkinson's Disease Including the Management of Sialorrhea. , 2022, , 145-154.		0
7	Levodopa+entacapone+carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642211080.	1.5	28
8	Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity. <i>PM and R</i> , 2021, 13, 1079-1093.	0.9	2
9	A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. <i>Journal of Parkinson's Disease</i> , 2021, 11, 187-198.	1.5	31
10	Reply to: Sudden Death In Parkinson's Disease: Treating Hypertension In The Elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 937-938.	0.9	1
11	Use of Botulinum Neurotoxin in Parkinson's Disease: A Critical Appraisal. <i>Toxins</i> , 2021, 13, 87.	1.5	11
12	Dose per muscle in cervical dystonia: pooled data from seven movement disorder centres. <i>Neurologia i Neurochirurgia Polska</i> , 2021, 55, 174-178.	0.6	2
13	The final diagnoses of patients with clinically suspected atypical parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 57-58.	1.1	1
14	Botulinum neurotoxin in cervical dystonia revisited – recent advances and unanswered questions. <i>Neurologia i Neurochirurgia Polska</i> , 2021, 55, 125-132.	0.6	5
15	Spasticity in practice (SPACE): an international non-interventional study of botulinum neurotoxin type A in treatment-naïve subjects with spasticity. <i>Neurologia i Neurochirurgia Polska</i> , 2021, 55, 165-173.	0.6	2
16	Botulinum neurotoxin in neurological practice – a leading topic in neurology. <i>Neurologia i Neurochirurgia Polska</i> , 2021, 55, 120-124.	0.6	1
17	The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature. <i>Journal of Clinical Neuroscience</i> , 2021, 90, 178-183.	0.8	28
18	Kindness in science does matter. <i>Journal of Neural Transmission</i> , 2021, , 1.	1.4	1

#	ARTICLE	IF	CITATIONS
19	A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients. Expert Review of Neurotherapeutics, 2021, 21, 1059-1068.	1.4	9
20	Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2207-2208.	2.2	0
21	OnabotulinumtoxinA Treatment in Patients with Upper Limb and Lower Limb Spasticity from the ASPIRE Study. Archives of Physical Medicine and Rehabilitation, 2021, 102, e21-e22.	0.5	0
22	Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study. Journal of the Neurological Sciences, 2021, 429, 119425.	0.3	0
23	An updated calculator for determining levodopa-equivalent dose. Neurological Research and Practice, 2021, 3, 58.	1.0	16
24	Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of dopamine agonists: Findings from the real-world OPTIPARK study. Journal of the Neurological Sciences, 2021, 429, 119432.	0.3	0
25	Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients. Journal of Parkinson's Disease, 2020, 10, 89-97.	1.5	27
26	Frequency of different subtypes of cervical dystonia: a prospective multicenter study according to Colâ€™Cap concept. Journal of Neural Transmission, 2020, 127, 45-50.	1.4	23
27	Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks. Parkinsonism and Related Disorders, 2020, 70, 23-30.	1.1	29
28	Impact of early intervention with onabotulinumtoxinA treatment in adult patients with post-stroke lower limb spasticity: results from the double-blind, placebo-controlled, phase 3 REFLEX study. Journal of Neural Transmission, 2020, 127, 1619-1629.	1.4	3
29	Is It Meanwhile Biomedical Sciences or Still â€™Ars Medicaâ€™?. Cells, 2020, 9, 2313.	1.8	0
30	Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome. Clinical Nuclear Medicine, 2020, 45, 283-287.	0.7	14
31	Management of Pain in Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, S37-S48.	1.5	38
32	What are the considerations for anti-hypertensive treatment in patients with Parkinson's disease?. Expert Opinion on Pharmacotherapy, 2020, 21, 1127-1130.	0.9	7
33	High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study. Toxicon: X, 2020, 7, 100040.	1.2	4
34	The Progressive Supranuclear Palsy Clinical Deficits Scale. Movement Disorders, 2020, 35, 650-661.	2.2	31
35	Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study. PM and R, 2020, 12, 1120-1133.	0.9	13
36	Parkinsonian Drugs: Indications. , 2020, , 1-19.		2

#	ARTICLE	IF	CITATIONS
37	Tremor in Idiopathic Cervical Dystonia – Possible Implications for Botulinum Toxin Treatment Considering the Col-Cap Classification. Tremor and Other Hyperkinetic Movements, 2020, 10, 13.	1.1	12
38	Influence of levodopa on orthostatic hypotension in Parkinson’s Disease. Neurologia I Neurochirurgia Polska, 2020, 54, 200-203.	0.6	13
39	Cervical dystonia – improving the effectiveness of botulinum toxin therapy. Neurologia I Neurochirurgia Polska, 2020, 54, 232-242.	0.6	11
40	Preferred muscles in cervical dystonia. Neurologia I Neurochirurgia Polska, 2020, 54, 277-279.	0.6	7
41	The challenge of pain in the pharmacological management of Parkinson’s disease. Expert Opinion on Pharmacotherapy, 2019, 20, 1847-1854.	0.9	16
42	Therapy of Sialorrhea with Botulinum Neurotoxin. Neurology and Therapy, 2019, 8, 273-288.	1.4	27
43	Dynamics of device-based treatments for Parkinson’s disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. Journal of Neural Transmission, 2019, 126, 879-888.	1.4	7
44	±-Synuclein in Parkinson’s disease: causal or bystander?. Journal of Neural Transmission, 2019, 126, 815-840.	1.4	88
45	Dyskinesia in multiple system atrophy and progressive supranuclear palsy. Journal of Neural Transmission, 2019, 126, 925-932.	1.4	11
46	Hypersalivation: update of the German S2k guideline (AWMF) in short form. Journal of Neural Transmission, 2019, 126, 853-862.	1.4	20
47	SIAXI. Neurology, 2019, 92, e1982-e1991.	1.5	79
48	Time for a new definition of Parkinson’s disease. Journal of Neural Transmission, 2019, 126, 801-801.	1.4	0
49	Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study. Journal of the Neurological Sciences, 2019, 399, 44-50.	0.3	7
50	Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers. Cells, 2019, 8, 151.	1.8	26
51	Torticaput versus Torticollis: Clinical Effects with Modified Classification and Muscle Selection. Tremor and Other Hyperkinetic Movements, 2019, 9, .	1.1	3
52	Symptomatic medication of 97 patients with multiple system atrophy parkinsonian subtype: An observational study. Basal Ganglia, 2018, 12, 4-7.	0.3	2
53	OnabotulinumtoxinA for the Treatment of Poststroke Distal Lower Limb Spasticity: A Randomized Trial. PM and R, 2018, 10, 693-703.	0.9	46
54	Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhea. Toxicon, 2018, 156, S86-S87.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Real-World Use of OnabotulinumtoxinA for Lower Limb Spasticity: Adult Spasticity International Registry (ASPIRE). Archives of Physical Medicine and Rehabilitation, 2018, 99, e9-e10.	0.5	0
56	Poster 68: IncobotulinumtoxinA for Sustained Improvement in Sialorrhea in Parkinson's Disease, Stroke, and Other Etiologies: Long-term Results from a Phase 3 Study. PM and R, 2018, 10, S28-S29.	0.9	0
57	Timing and Kinetics of Nonmotor Fluctuations in Advanced Parkinson's Disease. Journal of Parkinson's Disease, 2017, 7, 325-330.	1.5	13
58	Differentiation of atypical Parkinson syndromes. Journal of Neural Transmission, 2017, 124, 997-1004.	1.4	30
59	An update on the recognition and treatment of autonomic symptoms in Parkinson's disease. Expert Review of Neurotherapeutics, 2017, 17, 791-799.	1.4	7
60	An essay on the shaking palsy 200 years old. Journal of Neural Transmission, 2017, 124, 899-900.	1.4	19
61	Autonomic disturbances including impaired hand thermoregulation in multiple system atrophy and Parkinson's disease. Journal of Neural Transmission, 2017, 124, 965-972.	1.4	14
62	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations. JAMA Neurology, 2017, 74, 216.	4.5	171
63	How Do I Treat Cervical Dystonia With Botulinum Toxin by Using Ultrasound?. Movement Disorders Clinical Practice, 2017, 4, 647-647.	0.8	1
64	Autonomic Dysfunction in Parkinson's Disease: Cardiovascular Symptoms, Thermoregulation, and Urogenital Symptoms. International Review of Neurobiology, 2017, 134, 771-785.	0.9	21
65	Poster 79: The Adult Spasticity International Registry (ASPIRE) Study: 1 Year Results. PM and R, 2017, 9, S162.	0.9	0
66	The botulinum toxin legend of Reinhard Heydrich's death. Neurology, 2017, 89, 84-87.	1.5	1
67	Patients' perspective on current treatment options for Parkinson's Disease. Basal Ganglia, 2017, 9, 7-11.	0.3	4
68	Anatomy and cervical dystonia. Journal of Neural Transmission, 2017, 124, 237-243.	1.4	25
69	SIAXI: IncobotulinumtoxinA for Sialorrhea in Parkinson's Disease, Stroke, and Other Etiologies-Phase III Results. Archives of Physical Medicine and Rehabilitation, 2017, 98, e161.	0.5	0
70	Adult Spasticity International Registry Study: methodology and baseline patient, healthcare provider, and caregiver characteristics. Journal of Rehabilitation Medicine, 2017, 49, 659-666.	0.8	8
71	Assessment of Nonmotor Fluctuations Using a Diary in Advanced Parkinson's disease. Journal of Parkinson's Disease, 2016, 6, 597-607.	1.5	19
72	Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized controlled trial. Movement Disorders, 2016, 31, 1649-1657.	2.2	35

#	ARTICLE	IF	CITATIONS
73	Preface. Journal of Neural Transmission, 2016, 123, 1-2.	1.4	7
74	The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson's disease. Journal of Neural Transmission, 2016, 123, 51-55.	1.4	30
75	Parkinson's disease between internal medicine and neurology. Journal of Neural Transmission, 2016, 123, 3-17.	1.4	34
76	Advanced stages of PD: interventional therapies and related patient-centered care. Journal of Neural Transmission, 2016, 123, 31-43.	1.4	34
77	Intraindividual Variability of Nonmotor Fluctuations in Advanced Parkinson's Disease. Journal of Parkinson's Disease, 2015, 5, 737-741.	1.5	11
78	Selection of Muscles for Botulinum Toxin Injections in Cervical Dystonia. Movement Disorders Clinical Practice, 2015, 2, 224-226.	0.8	29
79	A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. Movement Disorders Clinical Practice, 2015, 2, 170-174.	0.8	19
80	Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Design, Development and Therapy, 2015, 9, 1913.	2.0	27
81	Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement. Journal of Neural Transmission, 2015, 122, 1457-1463.	1.4	45
82	Severity of orthostatic hypotension in the course of Parkinson's disease: No correlation with the duration of the disease. Parkinsonism and Related Disorders, 2015, 21, 314-316.	1.1	22
83	"Similar To" Is Not "Identical With", and "Identical With" Is Not "The Same As". Drugs in Research and Development, 2015, 15, 11-12.	1.1	1
84	Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS). Journal of Neural Transmission, 2015, 122, 1673-1684.	1.4	52
85	Nonmotor symptoms and focal cervical dystonia: Observations from 102 patients. Basal Ganglia, 2014, 4, 117-120.	0.3	37
86	Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data. Journal of Medical Economics, 2014, 17, 803-809.	1.0	4
87	Influence of the Nonergot Dopamine Agonist Pribedil on Vigilance in Patients With Parkinson Disease and Excessive Daytime Sleepiness (PivCog-PD). Clinical Neuropharmacology, 2014, 37, 116-122.	0.2	31
88	Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: Results of the German "Austrian open-label post-marketing surveillance prospective study. Journal of the Neurological Sciences, 2014, 337, 86-90.	0.3	29
89	Improvement of SF-36 scores in cervical dystonia patients "Is there a treatment effect when evaluating subscales?". Basal Ganglia, 2014, 4, 75-80.	0.3	4
90	Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration. Expert Opinion on Drug Safety, 2014, 13, 447-458.	1.0	19

#	ARTICLE	IF	CITATIONS
91	AbobotulinumtoxinA for the treatment of upper limb spasticity. <i>Clinical Investigation</i> , 2014, 4, 847-865.	0.0	1
92	Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease. <i>European Review for Medical and Pharmacological Sciences</i> , 2014, 18, 3349.	0.5	2
93	Rasagiline in Parkinson's disease: the show must go on. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 797-800.	1.0	0
94	Urological problems in Parkinson's disease: clinical aspects. <i>Journal of Neural Transmission</i> , 2013, 120, 587-591.	1.4	33
95	Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy. <i>Journal of Neural Transmission</i> , 2013, 120, 487-496.	1.4	94
96	Nonmotor fluctuations in Parkinson disease. <i>Neurology</i> , 2013, 80, 800-809.	1.5	284
97	Reduced Body Mass Index in Parkinson's Disease. <i>Journal of Nervous and Mental Disease</i> , 2013, 201, 76-79.	0.5	16
98	Classification of posture in poststroke upper limb spasticity. <i>International Journal of Rehabilitation Research</i> , 2012, 35, 227-233.	0.7	95
99	Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson's disease. <i>Basal Ganglia</i> , 2012, 2, S17-S26.	0.3	19
100	Drug interactions with selegiline versus rasagiline. <i>Basal Ganglia</i> , 2012, 2, S27-S31.	0.3	6
101	Treatment of dopa-responsive dystonia with Duodopa®. <i>Basal Ganglia</i> , 2012, 2, 159-161.	0.3	2
102	Validity of the DESPAR questionnaire as a new screening tool for depression in Parkinson's disease. <i>Basal Ganglia</i> , 2011, 1, 97-103.	0.3	3
103	Nondipping in Parkinson's Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-5.	0.6	35
104	Clinical data on the prolonged-release formulation of ropinirole for Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2011, 1, 79-86.	1.2	0
105	Drug-induced impulse control disorders in Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 323-327.	1.8	15
106	Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm. <i>Journal of Neural Transmission</i> , 2011, 118, 925-943.	1.4	36
107	A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis. <i>BMJ Open</i> , 2011, 1, e000196-e000196.	0.8	29
108	Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 1387-1393.	1.4	57

#	ARTICLE	IF	CITATIONS
109	Utility of the WHOâ€œfive wellâ€œbeing index as a screening tool for depression in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 777-783.	2.2	48
110	Efficacy and tolerability of rasagiline in daily clinical use â€œ a postâ€œmarketing observational study in patients with Parkinsonâ€™s disease. <i>European Journal of Neurology</i> , 2010, 17, 1164-1171.	1.7	25
111	The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey. <i>International Journal of Rehabilitation Research</i> , 2010, 33, 199-204.	0.7	70
112	Importance of <sup>123</sup> I-Metaiodobenzylguanidine Scintigraphy/Single Photon Emission Computed Tomography for Diagnosis and Differential Diagnostics of Parkinson Syndromes. <i>Neurodegenerative Diseases</i> , 2010, 7, 341-347.	0.8	27
113	Gastrointestinal dysfunction in Parkinson's Disease. <i>Journal of the Neurological Sciences</i> , 2010, 289, 69-73.	0.3	180
114	Early Detection of Parkinsonâ€™s Disease: Unmet Needs. <i>Neurodegenerative Diseases</i> , 2008, 5, 137-139.	0.8	14
115	Randomized, Double-blind, Placebo-Controlled Trial on Symptomatic Effects of Coenzyme Q10 in Parkinson Disease. <i>Archives of Neurology</i> , 2007, 64, 938.	4.9	183
116	Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN??) in Focal Dystonia. <i>Drugs</i> , 2007, 67, 669-683.	4.9	117
117	Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1004-1008.	2.2	91
118	Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson's Disease. <i>The Open Neurology Journal</i> , 2007, 1, 1-4.	0.4	11
119	Botulinum toxin: Clinical use. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 331-355.	1.1	105
120	Gait analysis in patients with advanced Parkinson disease: different or additive effects on gait induced by levodopa and chronic STN stimulation. <i>Journal of Neural Transmission</i> , 2006, 113, 163-173.	1.4	52
121	Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. <i>Journal of Neural Transmission</i> , 2006, 113, 303-312.	1.4	233
122	Botulinum toxin in multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, i16-i20.	1.8	18
123	Clinical studies with ropinirole in Parkinsonâ€™s disease and RLS. <i>Journal of Neurology</i> , 2006, 253, iv16-iv21.	1.8	2
124	The Parkinson-Control study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 500-509.	2.2	41
125	Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. <i>Brain</i> , 2006, 129, 1188-1193.	3.7	124
126	High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. <i>Journal of Neural Transmission</i> , 2005, 112, 649-660.	1.4	173



#	ARTICLE	IF	CITATIONS
127	Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX®) in healthy volunteers. <i>Journal of Neural Transmission</i> , 2005, 112, 905-913.	1.4	90
128	A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. <i>Neurology</i> , 2005, 64, 1949-1951.	1.5	267
129	Ropinirole, a Non-ergoline Dopamine Agonist. <i>CNS Neuroscience &amp; Therapeutics</i> , 2005, 11, 253-272.	4.0	32
130	Duloxetine in the treatment of stress urinary incontinence. <i>Therapeutics and Clinical Risk Management</i> , 2005, 1, 259-64.	0.9	13
131	Autonomic nervous system dysfunction in lightning and electrical injuries. <i>NeuroRehabilitation</i> , 2005, 20, 19-23.	0.5	8
132	Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. <i>Clinical Autonomic Research</i> , 2004, 14, 220-7.	1.4	30
133	Botulinum Toxin A in Anal Fissure: Why Does It Work?. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 257-258.	0.7	4
134	Autonomic dysfunctions in idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2003, 250, i28-i30.	1.8	72
135	Constipation in Idiopathic Parkinson's Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 681-686.	0.6	36
136	Drug interactions in the treatment of Parkinson's disease. <i>Journal of Neurology</i> , 2002, 249, 1-1.	1.8	9
137	Ten years' experience with botulin toxin in anal fissure. <i>International Journal of Colorectal Disease</i> , 2002, 17, 298-302.	1.0	39
138	Electrophysiologic testing of pelvic floor: some remarks. <i>Diseases of the Colon and Rectum</i> , 2002, 45, 708-10; author reply 709-10.	0.7	0
139	Botulinum toxin type B in the treatment of anal fissures. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 1721-1722.	0.7	12
140	Penile and perianal pudendal nerve somatosensory evoked potentials in the diagnosis of erectile dysfunction. <i>International Journal of Impotence Research</i> , 2001, 13, 89-92.	1.0	12
141	Vaginal versus anal stimulierte Pudenduslatenz - ein Vergleich. <i>Aktuelle Neurologie</i> , 2001, 28, 388-390.	0.1	2
142	Seltene und neuere Indikationen für Botulinumtoxin. <i>Klinische Neurophysiologie</i> , 2001, 32, 232-236.	0.2	1
143	EMG of the external anal sphincter. <i>Diseases of the Colon and Rectum</i> , 2000, 43, 116-117.	0.7	17
144	Botulinum Toxin in the Treatment of Neurological Disorders of the Autonomic Nervous System. <i>Archives of Neurology</i> , 1999, 56, 914.	4.9	59

#	ARTICLE	IF	CITATIONS
145	Equivalent doses of ropinirole and bromocriptine. <i>European Journal of Neurology</i> , 1999, 6, 618-618.	1.7	6
146	Repeat botulin toxin injections in anal fissure: in patients with relapse and after insufficient effect of first treatment. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1588-1589.	1.1	63
147	Incidence of anal fissure in nonselected neurological patients. <i>Diseases of the Colon and Rectum</i> , 1999, 42, 828.	0.7	7
148	Neurography of the pudendal nerve in pudendal canal syndrome. <i>Diseases of the Colon and Rectum</i> , 1999, 42, 281-282.	0.7	7
149	Das Parkinson-Syndrom als Modellerkrankung verschiedener Obstipationsformen. <i>Coloproctology</i> , 1999, 21, 7-12.	0.3	1
150	Ergotamininduzierte Rektumläsionen. <i>Coloproctology</i> , 1999, 21, 255-258.	0.3	4
151	Pudendus-SSEP in der Diagnostik anorektaler Funktionsstörungen. <i>Coloproctology</i> , 1999, 21, 80-83.	0.3	4
152	Treatment of drooling in Parkinson's disease with botulinum toxin. <i>Movement Disorders</i> , 1999, 14, 1057-1057.	2.2	76
153	Functional Outlet Obstruction: Anismus, Spastic Pelvic Floor Syndrome, and Dyscoordination of the Voluntary Sphincter Muscles: Definition, Diagnosis, and Treatment from the Neurologic Point of View. <i>Scandinavian Journal of Gastroenterology</i> , 1999, 34, 449-453.	0.6	32
154	Einfluß der Botulinumtoxininjektionen auf das Muskelaktionspotential des Musculus sphincter ani externus. <i>Coloproctology</i> , 1998, 20, 58-61.	0.3	1
155	Modifizierte Methode zur Bestimmung der linksseitigen Pudenduslatenz. <i>Coloproctology</i> , 1998, 20, 110-113.	0.3	2
156	Electrostimulation in fecal incontinence. <i>Diseases of the Colon and Rectum</i> , 1998, 41, 590-592.	0.7	19
157	Involuntary contractions of the striated anal sphincters as a cause of constipation. <i>Diseases of the Colon and Rectum</i> , 1998, 41, 258-260.	0.7	12
158	The impact of ropinirole on blood pressure and noradrenaline concentration after active orthostasis in Parkinsonian patients. <i>Parkinsonism and Related Disorders</i> , 1998, 4, 61-63.	1.1	10
159	Correspondence. <i>Urology</i> , 1998, 52, 352.	0.5	6
160	Treatment of Erectile Dysfunction by an External Ischiocavernous Muscle Stimulator. <i>European Urology</i> , 1998, 34, 355-359.	0.9	20
161	Gastrointestinal Motility Problems in Patients with Parkinson's Disease. <i>Drugs and Aging</i> , 1997, 10, 249-258.	1.3	151
162	The impact of bromocriptine on blood pressure, heart Rate and noradrenaline concentration after active orthostasis in Parkinson patients. <i>Parkinsonism and Related Disorders</i> , 1997, 3, 171-172.	1.1	1

#	ARTICLE	IF	CITATIONS
163	Is cardiovascular dysregulation in idiopathic Parkinson's syndrome correlated with decreased hormonal release?; TO THE EDITOR. European Journal of Neurology, 1997, 4, 199-200.	1.7	1
164	Influence of electrostimulation on the sphincteric compound muscle action potential in fecal incontinence. Coloproctology, 1997, 19, 247-249.	0.3	2
165	Elektrisch stimulierte Pudenduslatenz. Coloproctology, 1997, 19, 119-122.	0.3	7
166	One hundred cases of anal fissure treated with botulin toxin. Diseases of the Colon and Rectum, 1997, 40, 1029-1032.	0.7	198
167	Influence of botulinum toxin injections on the sphincteric compound muscle action potential of the external anal sphincter. Diseases of the Colon and Rectum, 1997, 40, 995-996.	0.7	7
168	Electromyogram of the external anal sphincter in amyotrophic lateral sclerosis. European Journal of Neurology, 1996, 3, 85-86.	1.7	8
169	Perianal thrombosis following injection therapy into the external anal sphincter using botulin toxin. Diseases of the Colon and Rectum, 1995, 38, 781.	0.7	62
170	Penile Sympathic Skin Response in Erectile Dysfunction. European Urology, 1995, 28, 314-319.	0.9	17
171	Botulinum toxin in therapy of anal fissure. Lancet, The, 1995, 345, 188-189.	6.3	56
172	Eye movement in amyotrophic lateral sclerosis: a longitudinal study. German Journal of Ophthalmology, 1995, 4, 355-62.	0.2	23
173	Surface versus needle electrodes in determination of motor conduction time to the external anal sphincter. International Journal of Colorectal Disease, 1994, 9, 197-199.	1.0	23
174	Are heart rate responses reproducible in the tilt-table test?. The Clinical Investigator, 1994, 72, 996-999.	0.6	2
175	Magnetic stimulation of the pudendal nerve. Diseases of the Colon and Rectum, 1994, 37, 697-699.	0.7	32
176	Therapy of anal fissure using botulin toxin. Diseases of the Colon and Rectum, 1994, 37, 1321-1324.	0.7	86
177	Colonic Transit Time in Nonidiopathic Parkinson's Syndrome. European Neurology, 1994, 34, 329-331.	0.6	24
178	Use of botulinum toxin in anal fissure. Diseases of the Colon and Rectum, 1993, 36, 974.	0.7	104
179	Anorectal ergotism. Induced by migraine therapy. Acta Neurologica Scandinavica, 1991, 84, 73-74.	1.0	15
180	Constipation in Parkinson's disease. Klinische Wochenschrift, 1991, 69, 906-909.	0.6	87

#	ARTICLE	IF	CITATIONS
181	Classification and diagnosis of cervical dystonia: Revived call for consensus. Movement Disorders Clinical Practice, 0, , .	0.8	2